Enatumab for relapsed or hard-to-treat warm antibody AIHA
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called enatumab for people with warm antibody autoimmune hemolytic anemia (wAIHA) that has come back or not improved after at least two prior treatments. The goal is to see if enatumab can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have primary warm antibody AIHA (not caused by another condition).
- Your disease has come back or not responded to at least two previous treatments (like steroids, rituximab, or other immune-suppressing drugs).
- Your hemoglobin level is between 60 and 100 g/L at the time of screening.
- Your liver and kidney function tests are within acceptable ranges.
- You have not received a CD20 antibody infusion in the last 3 months, and have stopped certain immune-suppressing drugs for at least 1 month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This trial tests a new cell therapy (YTS109) for people with autoimmune hemolytic anemia (AIHA) that has not responded to at least three prior treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new type of cell therapy (IASO206) for patients whose autoimmune hemolytic anemia (a condition where the body attacks its own red blood cells) has not responded to standard treatments. The therapy is designed to target and control the immune cells causing the problem.
This trial tests a drug called Linprixel for people with autoimmune hemolytic anemia (AIHA) that has come back or hasn't responded to at least two previous treatments. The goal is to see if it can help control the disease with manageable side effects.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.